Impact of the Systematic Use of the Criteria STOPP/START in Short Stay Geriatric. (REVOR)

August 4, 2020 updated by: Lille Catholic University

Impact of the Systematic Use of the Criteria STOPP/START in Short Stay Geriatric: Study of Superiority, Randomized, Controlled, Prospective, Single Blind

Assess the impact of the systematic use of STOPP/START tool during medication conciliation on the evolution of hospitalised elderly people's quality of life at 2 months.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

65

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Versailles, France, 78004
        • Hopital La Porte Verte

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

75 years and older (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patient with more than 75 years old
  • Hospitalized in geriatrics short-stay
  • Patient with a written informed consent
  • Patient with a social security scheme

Exclusion Criteria:

  • Severe dementia
  • Not able to respond to SF-12
  • Disease at final stage
  • Patient under legal protection (maintenance of justice, tutelage, legal guardianship)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: STOPP/START
Use of STOPP/START criteria during medication reconciliation
Procedure: STOPP/START criteria
software which helps to do the drug reconciliation
No Intervention: CONTROL
Medication reconciliation done as usual, without the consideration of the STOPP/START criteria

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
SF-12 Quality of life scale
Time Frame: at inclusion and at 2 months
The evolution of the hospitalised elderly people's quality of life at 2 months will be measured by the SF-12 scale.
at inclusion and at 2 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of falls
Time Frame: at 2 months
The number of falls during the two months following the inclusion will be collected for each patient.
at 2 months
Proportion of patients rehospitalized
Time Frame: at 2 months
The proportion of patients that have been rehospitalized (unscheduled hospitalization) during the two months following inclusion will be measured.
at 2 months
Mortality
Time Frame: at 2 months
The mortality during the two months following inclusion will be measured.
at 2 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Lille Catholic University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 16, 2018

Primary Completion (Actual)

July 17, 2018

Study Completion (Actual)

October 30, 2018

Study Registration Dates

First Submitted

January 2, 2018

First Submitted That Met QC Criteria

January 2, 2018

First Posted (Actual)

January 8, 2018

Study Record Updates

Last Update Posted (Actual)

August 5, 2020

Last Update Submitted That Met QC Criteria

August 4, 2020

Last Verified

August 1, 2020

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • RC-P0059

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Quality of Life

Clinical Trials on STOPP/START criteria

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe